Drug resistant epilepsy
Conditions
Brief summary
Percentage of 50% responders after 2 weeks and 6 weeks exposure to low and higher doses of clioquinol respectively (visit 3 and visit 5), Median % reduction of the seizure frequency at visit 5
Detailed description
Safety during trial (systematic recording of adverse events) Clinical neurological examination during the trial will identify children with possible neuropathy Adverse events will be reported (clinical and biochemical)., Assessment of seizure severity (NHS3 scale), Assessment of overall impact of seizures, medication side effects, comorbidities, and overall QoL (PIES).
Interventions
DRUGClioquinol
Sponsors
UZ Leuven
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of 50% responders after 2 weeks and 6 weeks exposure to low and higher doses of clioquinol respectively (visit 3 and visit 5), Median % reduction of the seizure frequency at visit 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety during trial (systematic recording of adverse events) Clinical neurological examination during the trial will identify children with possible neuropathy Adverse events will be reported (clinical and biochemical)., Assessment of seizure severity (NHS3 scale), Assessment of overall impact of seizures, medication side effects, comorbidities, and overall QoL (PIES). | — |
Countries
Belgium
Outcome results
None listed